Septerna (NASDAQ:SEPN) Insider Samira Shaikhly Sells 11,798 Shares

Septerna, Inc. (NASDAQ:SEPN) insider Samira Shaikhly sold 11,798 shares of Septerna stock in a transaction on Tuesday, May 26th. The shares were sold at an average price of $30.06, for a total transaction of $354,647.88. Following the completion of the sale, the insider directly owned 793 shares of the company’s stock, valued at approximately $23,837.58. The trade was a 93.70% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.

Samira Shaikhly also recently made the following trade(s):

• On Monday, March 2nd, Samira Shaikhly sold 70,453 shares of Septerna stock. The stock was sold at an average price of $28.10, for a total transaction of $1,979,729.30.

Septerna Stock Performance

Shares of Septerna stock traded up $1.26 during trading hours on Thursday, reaching $31.05. The company’s stock had a trading volume of 219,147 shares, compared to its average volume of 311,677. Septerna, Inc. has a one year low of $9.11 and a one year high of $32.63. The company has a market capitalization of $1.40 billion, a P/E ratio of -38.33 and a beta of 2.21. The stock’s fifty day simple moving average is $25.24 and its two-hundred day simple moving average is $25.98.

Septerna (NASDAQ:SEPN) last released its quarterly earnings data on Tuesday, May 12th. The company reported ($0.19) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.42) by $0.23. Septerna had a negative net margin of 49.88% and a negative return on equity of 12.72%. The firm had revenue of $26.52 million for the quarter, compared to analyst estimates of $16.98 million. As a group, research analysts forecast that Septerna, Inc. will post -1.61 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on SEPN shares. Wall Street Zen lowered shares of Septerna from a “buy” rating to a “hold” rating in a research note on Saturday, March 14th. Cantor Fitzgerald reiterated an “overweight” rating and set a $60.00 price target on shares of Septerna in a report on Tuesday, March 10th. Truist Financial increased their price target on Septerna from $34.00 to $35.00 and gave the company a “buy” rating in a research report on Wednesday, March 11th. Stifel Nicolaus started coverage on Septerna in a research note on Friday, May 1st. They set a “buy” rating and a $43.00 price objective on the stock. Finally, Zacks Research upgraded shares of Septerna from a “strong sell” rating to a “hold” rating in a research note on Tuesday, February 24th. One research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $43.13.

Hedge Funds Weigh In On Septerna

A number of hedge funds and other institutional investors have recently modified their holdings of SEPN. Group One Trading LLC increased its position in shares of Septerna by 111.8% during the fourth quarter. Group One Trading LLC now owns 944 shares of the company’s stock valued at $26,000 after acquiring an additional 8,955 shares during the last quarter. Global Retirement Partners LLC bought a new stake in Septerna during the fourth quarter worth $35,000. Russell Investments Group Ltd. bought a new stake in Septerna during the third quarter worth $36,000. Caitong International Asset Management Co. Ltd bought a new stake in Septerna during the fourth quarter worth $53,000. Finally, Mirae Asset Global Investments Co. Ltd. bought a new stake in Septerna during the fourth quarter worth $61,000.

About Septerna

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body.